Stocktoria
COMPUGEN LTD CGEN
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-08-01
COMPUGEN LTD financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6.0M | $2.0M | — | $17.8M | — | $712,000 |
| Gross profit | $63.5M | $19.9M | $31.5M | $6.5M | $5.3M | $1.9M | — | $16.8M | — | $489,000 |
| R&D expense | $22.8M | $24.8M | $34.5M | $30.6M | $28.7M | $22.8M | $19.8M | $30.3M | $28.6M | $24.5M |
| Operating income | $31.3M | -$14.9M | -$13.0M | -$35.4M | -$35.1M | -$31.5M | -$28.9M | -$23.2M | -$37.4M | -$32.6M |
| Income tax | $54,000 | $4.5M | $9.0M | $58,000 | $0 | $0 | -$722,000 | — | — | $20,000 |
| Net income | $35.3M | -$14.2M | -$18.8M | -$33.7M | -$34.2M | -$29.7M | -$27.3M | -$22.6M | -$37.1M | -$31.5M |
| EPS (diluted) | $0.38 | $-0.16 | $-0.21 | $-0.39 | $-0.41 | $-0.37 | $-0.43 | $-0.41 | $-0.72 | $-0.62 |
| Operating cash flow | $31.6M | $49.6M | -$35.9M | -$34.1M | -$22.7M | -$28.3M | -$27.9M | -$13.3M | -$30.7M | -$19.8M |
| Free cash flow | $31.3M | $49.5M | -$36.1M | -$34.6M | -$23.0M | -$28.5M | -$28.0M | -$13.4M | -$31.0M | -$22.4M |
| Cash & equivalents | $90.6M | $18.2M | $13.9M | $11.1M | $7.8M | $7.1M | $9.2M | $5.9M | $25.5M | $9.7M |
| Total assets | $156.6M | $115.0M | $121.3M | $94.2M | $132.2M | $138.3M | $53.8M | $53.2M | $38.7M | $71.1M |
| Shareholders' equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M | $119.8M | $38.3M | $37.2M | $29.3M | $63.5M |
Growth · year-over-year · Revenue CAGR 93.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +161.1% | -16.7% | +346.1% | +25.0% | +200.0% | — | — | — | — | -92.3% |
| Free cash flow growth | -36.7% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.